Phase 3 Results benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Piper Sandler Expands Investment Banking with the Hiring of Treavor Hill
Piper Sandler Expands Investment Banking with the Hiring of Treavor Hill
Piper Sandler Companies (NYSE: PIPR), a leading investment bank, is pleased to announce the addition of Treavor Hill as a managing director within the firms investment banking group. He will focus on the automotive and commercial vehicle aftermarkets and will be based in the firms Minneapolis office. Hill has over 10 years of investment banking experience focused on the aftermarket, executing both M&A advisory and growth/buyout financings. Prior to joining Piper Sandler, Hill was a senior vice president within the automotive aftermarket investment banking group at Jefferies. Prior to that, he was a vice president within the automotive aftermarket banking group at BB&T Capital Markets. Earlier in his career, Hill held various leadership roles in the commercial real estate industry.
Date: Feb. 2
StrataGraft, an investigational regenerative skin tissue therapy, is in development for the treatment of adult patients with deep partial-thickness thermal burns.
On Aug. 10, the FDA accepted the application for priority review, assigning a PDUFA goal date of Feb. 2.
Each year, approximately 40,000 patients in the U.S. require hospitalization for the treatment of severe burns, according to Mallinckrodt. Autograft, the current standard of care, involves surgical harvesting of healthy skin from an uninjured site on the patient and transplanting the skin graft to the injury, leaving the patient with more wounded areas requiring care.
StrataGraft skin tissue is engineered to mimic natural human skin with both inner dermis-like and outer epidermis-like layers.
Week Ahead In Pharma: Data Readouts Of COVID-19 Trials & FDA Decisions
THOUSAND OAKS (dpa-AFX) - The development and distribution of vaccines have been making headlines amid a surge in COVID-19 cases and this past week was no exception.
Novavax Inc. (NVAX), which was up 74%, was one of the top gainers for the week ending January 29, 2021, thanks to encouraging trial results of its COVID-19 vaccine candidate. In a phase III trial, conducted in UK, the two-dose regimen of Novavax vaccine NVX-CoV2373 has been found to have an efficacy rate of 89.3%.
Vaxart Inc. (VXRT), with returns of nearly 68%, was another winner of the week as the company reported new pre-clinical histology data showing that its oral vaccine protected against lung inflammation in hamster models.